Paroxysmal nocturnal hemoglobinuria (PNH) arises as the result of a somatic mutation affecting a pluripotent hematopoietic stem cell. The affected gene, called PIG-A (phosphatidylinositol glycan-class A) encodes a protein essential for normal biosynthesis of the glycosyl phosphatidylinositol (GPI) moiety that serves as a membrane anchor for many cellular proteins. The PIG-A mutations cause GPI-anchored proteins (GPI-AP) to be deficient on the hematopoietic elements of PNH. The deficiency of GPI-AP regulation of complement accounts for the hemolysis that is the hallmark of PNH. PNH is a clonal disease, and the circulating hematopoietic elements are a mosaic of normal and abnormal cells. For clinical evidence to become apparent, the PNH clone must expand so that signs and symptoms of hemolysis are observed. Thus, the abnormal clone appears to have a proliferative advantage.
In Specific Aim I we propose to determine if a mutation of PIG-A provides a proliferative advantage in vivo. Homologous recombination using two step gene replacement will be used to inactivate the gene after the mouse has fully developed.
In Specific Aim II, evidence for expression of PNH specific genes will be sought. Lymphocyte clones from a patient with PNH have been developed. Some clones normally express of GPI-AP (putatively the progeny of residual normal stem cells) and others are deficient (progeny of the abnormal clone). These clones should be genetically matched except for PNH specific differences. PNH specific genes will be identified and characterized using differential display polymerase chain reaction. The only curative therapy for PNH is marrow ablative chemotherapy followed by allogeneic bone marrow transplantation. In essentially all patients with PNH,. cells with normal expression of GPI-AP circulate along with cells that are GPI-AP deficient, suggesting that residual normal stem cells are present. If normal stem cells can be separated from abnormal stem cells, they could be used in autologous bone marrow transplantation.
In Specific Aim II, we will determine if PNH stem cells can be distinguished from normal. Studies aimed at determining the feasibility of purging GPI-AP negative cells from a mixture of GPI-AP positive and CPI-AP negative cells are also described.

Project Start
1998-09-22
Project End
2000-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Prasher, J M; Elenitoba-Johnson, K S; Kelley, L L (2001) Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia. Oncogene 20:2946-55
Mojica, M P; Perry, S S; Searles, A E et al. (2001) Phenotypic distinction and functional characterization of pro-B cells in adult mouse bone marrow. J Immunol 166:3042-51
Lok, C N; Ponka, P (2000) Identification of an erythroid active element in the transferrin receptor gene. J Biol Chem 275:24185-90
Hsieh, F F; Barnett, L A; Green, W F et al. (2000) Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase. Blood 96:2746-54
Wiesmann, A; Kim, M; Georgelas, A et al. (2000) Modulation of hematopoietic stem/progenitor cell engraftment by transforming growth factor beta. Exp Hematol 28:128-39
Spangrude, G J; Cooper, D D (2000) Paradigm shifts in stem-cell biology. Semin Hematol 37:10-Mar
Wiesmann, A; Phillips, R L; Mojica, M et al. (2000) Expression of CD27 on murine hematopoietic stem and progenitor cells. Immunity 12:193-9
Searles, A E; Pohlmann, S J; Pierce, L J et al. (2000) Rapid, B lymphoid-restricted engraftment mediated by a primitive bone marrow subpopulation. J Immunol 165:67-74
Wiesmann, A; Spangrude, G J (1999) Marrow engraftment of hematopoietic stem and progenitor cells is independent of Galphai-coupled chemokine receptors. Exp Hematol 27:946-55
Perry, S S; Kim, M; Spangrude, G J (1999) Direct effects of cyclosporin A on proliferation of hematopoietic stem and progenitor cells. Cell Transplant 8:339-44

Showing the most recent 10 out of 19 publications